

Anti-Cancer Drugs 2005

Key Word Index to Volume 16

- 11,11'-dideoxy-verticillin, 515
 5-aza-2'-deoxycytidine, 301
 5-fluorouracil, 285, 435, 495
 5F 203, 137
 5'-DFUR, 309
- $\alpha_v\beta_3$, 401
 ω -hydroxy fatty acids, 543
- acute lung injury, 743
 acute lymphoblastic leukemia, 631
 adamantylamine, 653
 additivity, 417
 adenocarcinoma, 739
 adenoid cystic carcinoma, 719
 adenoviral vector, 1053
 adhesion, 11, 293, 845
 adjuvant, 107
 advanced progressive renal cell carcinoma, 581
 advanced, 645
 adverse drug reactions, 923
 adverse events, 1029
 AGS 115, 776
 AKT, 977
 alcohol abuse, 199
 all-*trans*-retinoic acid, 151
 allopurinol, 569
 androgen suppression, 863
 angiogenesis, 151, 201, 211, 401, 757, 817, 1059
 animal model, 1059
 anorectal malignant melanoma, 345
 antagonism, 719
 antagonist, 159
 anthracycline resistant, 77
 anti-angiogenetic, 917
 anti-cancer drug, 1071, 1091
 anti-cancer, 945
 anti-estrogen, 559
 anti-leukemic activity, 1075
 anti-tumor, 107, 515, 917
 anti-tumor 1,4-anthracenediones, 953
 anti-tumor activity, 653
 anti-tumor effect, 1083
 antifolate, 285
 antileukemic activity, 151
 antisense CK2 α , 1037
 antisense oligodeoxynucleotide, 1037
- antitumor, 381
 apoptosis, 87, 119, 229, 263, 381, 393, 409, 507, 543, 593, 621, 776, 789, 837, 1037, 1045
 aromatase inhibitor, 879
 arsenic, 119
 aryl hydrocarbon receptor, 137
 atomic absorption spectrometry, 129
 ATP-based tumor chemosensitivity assay, 969
 auditory, 569
 autophagy, 776
 aziridinylbenzoquinones, 381
- B cell chronic lymphocytic leukemia, 277
 B-steroidal lactam, 1075
 Bax, 159, 507, 789, 977
 BAY 12-9566, 997
 Bcl-2, 159, 789
 Bcl-X_L, 789, 977
 BCR-ABL, 631
 bendamustine, 871
 benzidine staining, 635
 biliary elimination, 675
 biocompatibility, 727
 bisphosphonate, 11, 107, 845
 blood platelets, 659
 BLT₁, 467
 BLT₂, 467
 BMF, 871
 bombesin, 159
 bone marrow transplantation, 337
 bortezomib, 475
 brain metastases, 747
 brain tumor, 159
 breast cancer, 11, 77, 107, 137, 199, 441, 559, 569, 609, 683, 751, 845, 867, 1023, 1083
 butyrate, 373
- camptothecin, 763, 1099
 cancer, 119, 349, 475, 593, 901
 cancer cell lines, 653
 cancer cells, 229, 1037
 cancer therapy, 211, 601
 capecitabine, 39, 441
 carboplatin, 101, 945
 carcinoma, 911
 cardiopathy, 1017
 caspase, 263, 543
- caspase-independent pathway, 837
 casuarinin, 409
 cell cycle, 129, 409, 621, 789
 cell cycle arrest, 533
 cell cycle kinetics, 989
 cell differentiation, 635
 cell growth inhibition, 621
 cetuximab, 483
 chemoinducible gene therapy, 1053
 chemoprotection, 569
 chemosensitivity, 969
 chemosensitivity test, 525
 chemotherapy, 63, 185, 301, 361, 393, 455, 495, 551, 587, 997, 1053
 chemotherapy-induced anemia, 617
 children, 337
 chlorambucil, 1075
 cholesterol, 879
 chromosome breakage, 67
 chromosome delay, 67
 cisplatin, 101, 345, 455, 501, 569, 645, 659, 719, 733, 1009, 1029, 1091, 1109, 1129
 CK2, 1037
 clinical benefit, 191
 clinical development, 1
 clinical trial, 317, 1129
 clivus chordoma, 1139
 clonogenic growth, 1071
 CMF, 871
 collagen gel droplet culture drug-sensitivity test, 525
 collagen structural stability, 757
 collagen structure, 201
 colon, 495
 colon tumor, 533
 colorectal cancer, 31, 39, 483, 1099
 combination chemotherapy, 87
 combination therapy, 935, 945
 comet assay, 659
 COMPARE analysis, 145
 compatibility, 727
 compound 5, 837
 CPT-11, 31
 crystal structure, 1059
 cyclooxygenase, 507
 cyclooxygenase-2, 495
 cyclophosphamide, 331
 cystemustine, 1003
 cytarabine, 743
 cytidine deaminase, 301

- cytochrome P450, 349
- cytosine arabinoside, 59
- cytosine deaminase, 349
- cytotoxic agents, 417
- cytotoxic drug, 609, 845
- cytotoxic drugs, 11, 277
- cytotoxicity assay, 277
- cytotoxicity, 145, 167, 533

- D-penicillamine, 757
- D-penicillamine benzyl ester, 757
- D-penicillamine methyl and hexyl esters, 201
- D-steroidal lactam, 1075
- darbepoetin α , 617
- darbepoietin, 1023
- daunorubicin, 93
- demethylcantharidin, 825
- dermatofibrosarcoma protuberans, 461
- dexrazoxane, 93
- differentiation, 175
- dimethyl fumarate, 167
- discovery, 1
- disease specificity, 277
- DNA binding, 145
- DNA excision repairable lesions, 67
- DNA fragmentation, 263
- DNA incorporation, 285
- DNA methylation, 301
- DNA-damaging agent, 1053
- docetaxel, 21, 77, 441, 455, 885, 1023
- dose density, 1023
- dose escalation, 317
- dose intensity, 1029
- Doxil, 667
- doxorubicin, 93, 255, 423, 667, 945
- drug combination, 811
- drug discovery, 223
- drug resistance, 277
- drug–drug interactions, 331, 627, 675, 935
- Dunning tumor, 855

- ebselen, 569
- EF24, 263
- EFDAC, 776
- electrochemotherapy, 345
- ellipticine, 789
- endostatin, 551
- epidermal growth factor receptor, 191, 211, 483, 515, 739
- epidoxorubicin, 441
- epirubicin, 63, 1023

- Erk1/2, 515
- erlotinib, 483
- erythrocyte, 885
- erythroleukemia, 635
- esophageal cancer, 495
- established human carcinoma cell lines, 621
- estrogen receptor, 559, 751
- ET-743, 935
- every-2-week, 77
- Ewing's sarcoma, 101
- exemestane, 879
- expanded access program, 191

- farnesyltransferase inhibitor, 1059
- Fas ligand, 409
- Fas/APO-1, 409
- fatigue, 617
- fever, 59
- first line, 53
- first-line treatment, 871
- flow cytometry, 817
- fluorescence in situ hybridization, 67, 461
- folylpolyglutamate synthetase, 1
- free radicals, 93, 381

- G₂/M cell cycle arrest, 263
- G-quartet oligodeoxynucleotide, 601
- gastric cancer, 47, 435, 645
- gastrin-releasing peptide, 159
- gefitinib, 191, 483, 739, 747, 1123
- gemcitabine, 21, 551, 719, 885, 977, 1017, 1023, 1029, 1115, 1129
- gene therapy, 551, 1053
- genomics, 797
- genotoxicity, 805
- glioblastoma multiforme, 167
- glioblastoma, 323
- gliomas, 323
- glutathione peroxidase, 569
- glutathione, 263
- growth inhibition, 229
- guinea-pigs, 675

- H1299, 805
- head and neck cancer, 719
- head and neck neoplasms, 447
- head and neck squamous cell carcinoma, 719
- hematologic toxicity, 997
- hemolysis, 727
- hepatitis B reactivation, 83
- hepatotoxicity, 935
- Her-2/*neu*, 185

- herpes simplex virus, 349
- hexyl-3-(imino)propionitrile, 201
- high throughput assays, 683
- high-content screening, 593
- high-dose chemotherapy, 897, 1135
- high-dose ifosfamide, 733
- high-dose methotrexate, 733
- high-throughput screening, 593
- histone deacetylase, 373, 635
- HL60, 151
- HL-60 cell, 953
- HLA class I expression, 989
- horseradish peroxidase, 349
- human colon carcinoma cells, 129
- human colorectal cell line WiDr, 989
- human hepatocellular carcinoma, 825, 837
- human tumor cell lines, 1091
- human tumors, 1071
- human umbilical vein endothelial cell, 401
- hyaluronic ester, 373
- hydroxamic acid, 635
- hypercalcemia of malignancy, 1045
- hypopharynx, 447
- hypoxia inducible factor-1, 901
- hypoxia, 349, 901

- i.p. infusion, 1009
- i.v. busulfan, 337
- ibandronate, 107
- image analysis, 593
- imatinib mesylate, 461
- imatinib, 631
- Imexon, 727
- in vitro*, 609
- in vitro* assay, 223, 631
- in vitro* chemosensitivity, 87
- in vivo* efficacy, 423
- indolocarbazoles, 145
- induction chemotherapy, 867
- infusion simulation, 727
- inhibition, 145, 331
- integrin, 401
- interaction studies, 129
- interleukin-2, 581
- interferon, 581
- interleukin-6, 137
- intratumoral delivery, 423
- invasion, 11, 845
- Iressa, 1099
- irinotecan, 39, 495, 645, 811, 893, 1099
- iron, 93

- isolated mitochondria, 953
isoprostanes, 659
- K562, 635
- LA-12, 653
lamivudine prophylaxis, 83
lathrogen, 201
leptomeningeal carcinomatosis, 897
leucovorin, 47
leukemia, 59, 119, 175, 301, 911
leukotriene B₄, 467
lipid, 879
lipoprotein, 879
liposomal doxorubicin, 21
liver metastases, 199
locally advanced breast cancer, 21
lung cancer, 393
LY293111, 467
lymphocytes, 659
lysyl oxidase, 757
- magnetic resonance imaging, 855
mammalian cell lines, 223
mammary adenocarcinoma tumor stability, 201
matrix metalloproteinase, 201, 293, 757
matrix metalloproteinase inhibitor, 855
maximum tolerated dose, 1029
MCF7, 805
MDA-MB-231, 805
mechanism, 1109
mechanism of drug action, 901
median-effect analysis, 417
melanoma, 543, 757, 817
metabolism, 331, 935
metalloproteinase inhibitors, 997
metastatic bone disease, 11, 845
metastatic breast cancer, 185, 871, 1135
metastatic, 31, 709
metastatic melanoma, 53, 1003
mevalonate pathway, 11, 845
mice, 501
microsphere, 423
migration, 11, 845
mitochondria, 911
mitochondrial membrane depolarization, 263
mitochondrial membrane potential, 953
mitomycin C, 167, 423, 435
mouse, 1109
- mTOR, 533, 797
multidrug resistance, 255, 393
multidrug resistance-associated protein, 255
multimodal treatment, 1139
multiple myeloma, 475
murine Friend leukemic cell, 635
murine model, 757
- N*-methyl-*N'*-nitro-*N*-nitrosoguanidine, 507
nanocapsule, 1037
nanoparticle, 1037
neoadjuvant, 21, 31, 441
neoadjuvant chemotherapy, 323, 867
nephrotoxicity, 733
neuroblastoma, 101
neuropathy, 587
neuropeptides, 1083
neurotoxicity, 587
nevirapine, 627
new drugs, 211
NF- κ B, 137
nitrogen mustard steroidal esters, 67
nitroreductase, 349
nitrosourea, 1003
non-Hodgkin's lymphoma, 83
non-small cell lung cancer, 191, 243, 455, 483, 747, 1123, 1129
non-small-cell lung carcinoma, 945
norcantharidin, 293
novel treatment, 709
NQO1, 381
- oral availability, 751
organ distribution, 501
oropharynx, 447
osteolytic bone metastasis, 107
osteosarcoma, 667, 733
ototoxicity, 569
ovarian cancer, 243, 525, 569, 1009
oxaliplatin, 47, 587, 1017
oxidative stress, 659
oxidized glutathione, 263
- p53, 409
p53 activity, 805
p57KIP2 expression, 301
paclitaxel, 63, 243, 627, 1115
paclitaxel metabolism, 675
pAKT, 797
pancreatic cancer, 467
partition, 893
partition ratio, 885
- patellazole, 533
pathological complete response rate, 867
pegfilgrastim, 441, 1023
pegylated liposomal doxorubicin, 435
permeability transition, 911
peroxisome-proliferator activated receptor- γ , 467
perspective, 917
pharmacogenomics, 923
pharmacokinetics, 337, 349, 627, 1009, 1029
pharmacological synergism, 977
pharmacological targeting, 901
phase I dose escalation study, 47
phase II, 53
phase II study, 455
phase II trial, 1003
phase III, 1123
phase III trial, 871
phase I–II study, 1115
phosphatidylinositol-3-kinase, 977
phosphatidylserine externalization, 263
PI3K, 797
plasma, 885
platelet-derived growth factor, 461
platinum adducts, 129
platinum anti-cancer agents, 825
platinum complex, 653
platinum polymer conjugate, 501
plaunotol, 401
poly-L-glutamic acid, 243
polyamine analogs, 229
polyamine metabolism, 229
polyethylene glycol conjugate, 763
polyoxoanion, 101
polyoxometalate, 101
pre-operative chemotherapy, 867, 1023
precure mutant virus, 83
primary chemotherapy, 21
primary systemic therapy, 867
prodigiosin, 393
prolonged infusion, 1129
prostate cancer, 11, 63, 309, 855, 863, 1045
prostate cancer cell lines, 417
prostate secretory protein, 1045
proteasome, 475
protein kinase, 1037
protein kinase C, 159, 175
protein phosphatase inhibition, 825
proteomics, 683
proto-oncogene, 175

- PS-341, 475
 pulmonary metastases, 1139
 pulmonary metastasis, 293
 pure antagonist, 751
 pyrazolo[5,1-*c*][1,2,4]benzotriazine system, 621

 quality of life, 617

 radiotherapy, 323
 Raf kinase inhibitor, 129
 raltitrexed, 1
 rapamycin, 533, 797
 Ras, 1059
 rat, 667, 855
 reactive oxygen species, 93, 263, 817
 receptor-mediated endocytosis, 763
 recurrence, 1139
 red blood cell, 885, 893
 redox cycling, 381
 reduction–oxidation (redox), 263
 relapse, 897
 renal cell cancer, 1091
 renal cell carcinoma, 709
 renal failure, 1017
 resistance, 1099
 responsiveness, 739
 resveratrol, 659
 review, 917
 rhabdomyosarcoma, 811
 rituximab, 83

 S-1, 1109
 safety, 1123
 salvage chemotherapy, 39
 Schiff base cross-links, 201, 757
 second-line therapy, 581
 second-line treatment, 1003
 selectivity, 911
 sensitivity, 1099
 sesquiterpene, 776
 signal transduction, 129, 211, 317
 signet ring cell carcinoma, 87
 single-nucleotide polymorphism, 923
 site-specific delivery, 763
 small cell lung cancer, 361
 smoking, 893
 SMS 201-995 (octreotide), 989

 SN-38, 811, 1099
 sodium butyrate, 255
 solid tumors, 423
 somatic mutations, 739
 squamous cell cancer of the head and the neck, 1115
 squamous cell carcinoma, 447
 squamous cell carcinoma of the head and neck, 483
 stability, 727
 Stat3, 601
 stem cell transplantation, 1135
 steroid, 743
 steroidal analogs, 151
 steroidal ester, 1075
 stomach neoplasm, 87
 streptonigrin, 167
 structure–activity relationships, 67, 1075
 suicide gene therapy, 349
 survival, 31
 synergism, 417
 synergy, 719
 syngeneic model, 763
 synthetic curcumin analog, 263
 systemic palliative therapy, 1139
 systemic therapy, 709
 systemic treatment, 667

 T cell reinfusion, 1135
 tachykinin receptor, 1083
 tamoxifen, 323, 559, 879
 tanshinone derivative 278E, 175
 target therapy, 461
 targeted drug, 709
 taurolidine, 917
 taxane, 243
 Taxotere, 309
 tegafur, 447
 tegafur–uracil, 47
 testicular cancer, 897
 thalidomide, 581
 therapeutics, 797
 therapy, 917, 1037
 thymidine kinase, 349
 thymidine phosphorylase, 285
 thymidylate synthase, 1, 285
 thyroid cancer, 255
 thyroid function test, 863

 time-dependent pharmacologic effect, 285
 titanocene dichloride, 1071
 titanocene, 1091
 TNP-470, 817
 topiramate, 587
 topoisomerase I, 145
 toxicity, 423, 501
 trabectedin, 811
 traditional Chinese medicine, 825
 transcriptional targeting, 1053
 translation, 533
 trastuzumab, 185, 199
 treatment, 361
 trifluorothymidine, 285
 trifunctional antibody, 1135
 triglycerides, 879
 tumor invasion, 293
 tumor necrosis factor- α , 667
 type II DNA topoisomerase, 93
 tyrosine kinase inhibitor, 719

 unfit, 1017
 uracil, 447
 urothelial cancer, 1017
 usnic acid, 805
 uterine cancer, 525
 uterus, 559

 vascular endothelial growth factor, 159
 vascular endothelial growth factor receptor-1, 515
 venlafaxine, 587
 vinorelbine, 53, 77
 viral gene therapy, 1053
 vitamin K, 837

 weekly administration, 455

 xanthine oxidase, 569
 Xeloda, 309
 xenograft, 825, 945
 xenograft cancer, 1037
 XR5944, 945

 ZD9331, 1
 zebularine, 301
 zoledronic acid, 969